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Abstract
The aim of the given study was to improve the results of treatment of patients with concretions of the upper third of the ureter.
Materials and methods. The clinical trial was carried out as a non-interventional open, controlled, in two groups of patients 
with baseline control. The inclusion criteria concerned the patients with concretions of the upper third of the ureter 0.7−0.9 mm in 
size, which had one session of an extracorporeal shock-wave lithotripsy (ESWL), and after the procedure the size of the concretions 
fragments was up to 3 mm. The study involved 60 patients, all patients in the main group (n=30) were treated using phytotherapy, 
within 1 month starting with basic therapy under hospital conditions and continuing with preventative treatment in an outpatient 
setting. The control group (n=30) received baseline therapy (up to 10 days) at the stationary stage.
Results and discussion. In patients of the main group, fragments of concretions came out significantly faster, namely: in 
the main group, the fragments came out in 21 patients (70.0 %), while in the control group in 15 patients (50.0 %) (p1−p2, p<0.05) to 
the 7th day, and in the main group, the fragments came out in one patient more than 14 days, and in the control group – in 5 patients, 
p<0.05. The “stone path” in the bottom third of the ureter was in 1 patient (3.3 %) of the main group and in 3 patients (10.0 %) in 
the control group (p1−p2, p<0.05). The “stone path” departure time in patients of the main group was 2 days, and in patients of the 
control group it was 4.1 days from the time of its formation (p1−p2, p <0.05). Bacteriuria was observed in the main group on the 10th 
day 6.6 % less relative to the control group.
Conclusion. At comparing the obtained results in patients of both groups in 1 month it was noted that high efficacy of the 
treatment was registered in 6 (20 %) patients of the main group and in 3 patients (10 %) of the control group (p<0.05), moderate 
efficiency was registered in 23 (76.7 %) patients of the main group and in 22 (73.3 %) patients of the control group respectively, low 
efficacy was registered in 1 (3.33 %) patient in the main group and 5 (16.7 %) patients of the control group (p<0,05), which points to 
the effectiveness of Urolesan capsules use in complex therapy of patients with concretions of the one third of ureter.
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1. Introduction
The prevalence of urolithiasis disease (UD), among all urological diseases, is second after 
urinary tract infections [1, 2]. Recently, this indicator in Ukraine increased 1.2 times, the number 
of patients reaches over 160 thousand people – this is 973.5 cases per 100 000 adult population. 
The rates of prevalence increase are 0.16–0.22, the frequency of UD reaches 30–45 % of the 
total urological pathology. Mostly, young people of working age suffer from this disease, 70 % 
of patients aging from 20 to 50 years old. The disease can occur with the acute or chronic pyelo-
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nephritis, frequent recurrence of UD (30–80 %), which, in turn, leads to renal failure, disability 
and mortality in patients [3].
UD etiology and pathogenesis have not been completely determined until now. Kidney 
stones genesis is divided into causal and formal. Causal focuses on etiological factors; formal 
explains physico-chemical conditions of the concretions formation and conditions promoting the 
stone formation process. The stone formation pathogenesis in kidneys is divided depending on the 
type of crystalluria, urine pH, excretion of one or another type of mineral salts, urine and oxalic 
acids, their salts, sodium, ammonium, magnesium and other factors [4, 5].
In some cases, UD develops against the background of calcium increased excretion during 
systemic skeletal diseases and severe bone injuries. In case of purine metabolism disorders 
(gout), urolithiasis disease is often associated with it. Endogenous factors, such as drinking wa-
ter, food, micronutrients or vitamins deficiency, as well as some drugs have a certain role in UD 
formation [6, 7].
Implementation of the extracorporeal shock-wave lithotripsy significantly improved the ef-
ficacy of UD therapy, in particular for concretions sized > 6 mm; and nowadays, it is the most ef-
fective non-invasive method applied for UD treatment [8]. In the treatment of ureterolithiasis by the 
ESWL method, complications may occur that affect the duration and tactics of patient management 
in the postoperative period. After ESWL, formation of a “stone path” is observed in 7 % of cases, 
one of the causes of which is fixation of the group of concretions fragments in a limited section 
of ureter with the development of its mucous membrane edema, herewith, more than 70 % of the 
“stone path” are formed in the lower third of the ureter [9, 10].
It should also be mentioned that the concretions fragments after disintegration can not al-
ways come out quickly due to the change of urodynamics of the upper urinary tract, spastic reaction 
of the ureter after ESWL and micro injuries by the stones fragments of the ureter. A lot of drugs 
have been proposed for medical therapy and concretions removal. Nowadays, selective alpha ad-
renergic antagonists (α1A and α1D), β-receptor agonists (β2 and β3), 5-HT3 receptor antagonists, 
prostaglandin and cyclooxygenase antagonists, phosphodiesterase inhibitors, potassium channel 
openers and calcium channel blockers, NO-donor and Ro-kinase inhibitors are considered to be 
agents that can cause ureter wall relaxation and thus contribute to the concretions fragments re-
moval after ESWL [13, 14].
Modern tasks for medicinal specialists involved in the treatment of patients with urolithiatic 
disease are both preventative measures, as well as measures aimed at preventing of the stones for-
mation, their removal, and prescriptions of remedies that promote the removal of stones fragments, 
after a non-invasive treatment, with the minimal risk of complications.
Recently, phytotherapeutic remedies are becoming increasingly popular in the treatment of 
many urological diseases. This mainly depends on their availability and relative safety, as well as 
their good tolerability. However, the role of phytotherapeutic remedies in the treatment of patients 
with urolithiatic disease, in particular with ureteral concretions after a non-invasive treatment, has 
not been adequately studied.
Ukrainian scientists developed a multicomponent drug Urolesan, capsules containing herb-
al extracts: 1 capsule contains urolesan thick extract with 10 % moisture – 10.70 mg (contains dry 
residue: wild carrot fruit (Fructi Dauci carotae) (1:1) – 1.84 mg (extractant ethanol 96 %), common 
hop cones (Strobuli Humuli lupuli) (1:1) – 6.33 mg (extractant ethanol 96 %), Oregano herb (Herba 
Origani vulgaris) (1:1) – 1.46 mg (extractant ethanol 96 %)); Peppermint oil – 7.46 mg; Fir needle 
essential oil – 25.50 mg.
Ethanol extract of wild carrot seeds shows antispasmodic, diuretic, bactericidal, and anti- 
inflammatory effects.
Ethanol extract of hop cones is used for neurasthenia, insomnia, neuralgia, in liver diseases, 
spleen disorders, radiculitis and joint diseases. It has anti-ulcer, estrogen-like, anti-inflammatory 
(especially for inflammatory diseases of kidneys, urinary and gallbladder), diuretic action. Reme-
dies containing hop cones are traditionally used in the treatment of acute and chronic pyelonephri-
tis, as a painkiller for renal stone disease and cystitis.
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Alcohol extract of oregano herb is used as expectorant, diaphoretic, anti-inflammatory, and 
sedative agent. Peppermint oil shows a sedative, antispasmodic, and choleretic effect.
Fir needle essential oil is a material for oil solutions and emulsions, containing fat-soluble 
vitamins, which, in combination with compounds of silicon, magnesium, and potassium, prevent 
crystalline formation, growth and aggregation of crystals of oxalate and calcium phosphate.
Urolesan has a wide range of pharmacotherapeutic effects, typical for standardized drugs 
of synthetic originn. The substantiation of the efficiency of the drug as a basic or complex therapy 
in the treatment of urolithiasis in acute and chronic infections of the bladder and kidneys is rather 
interesting, since the most common cases for the use of the drug are various forms of urolithiatic 
disease, as well as acute and chronic pyelonephritis.
Thus, all of the above-mentioned Urolesan properties determined the pathogenetic reason-
ableness of its use during the study in area of the treatment of patients with concretions of the upper 
third of the ureter after the session of extracorporeal ultrasound lithotripsy.
2. Aim of research
The am of the given study was to estimate efficiency and safety of the use of Urolesan in 
patients with concretions of the upper third of the ureter after ESWL.
3. Materials and methods
The clinical trial was carried out as a non-interventional open, controlled, in two groups of 
patients with baseline control. 
The inclusion criteria concerned: the patients aged 18 to 65 years; with diagnosis: urolithi-
atic disease, concretions of the upper third of the ureter (only 0.7–0.9 mm in size); efficiency of the 
first ESWL session (after the procedure the size of the concretions fragments was up to 3 mm); 
informed written agreement of the patient to participate in the study.
The exclusion criteria were: increased sensitivity to any component of the drug; inefficiency 
of the first ESWL session or after the procedure the size of the concretions fragments was more than 
3 mm; participation in any other clinical trial; congenital malformations of the urinary and excretory 
system organs; active inflammatory process in the urinary tract; cardiovascular disease; diabetes; 
immunodeficiency states; pregnancy; neurogenic bladder disorders; disorders of the blood circulatory 
system; gastritis (except gastritis with secretory insufficiency); stomach ulcer and duodenal ulcer.
The study involved 60 patients, having inpatient and outpatient treatment and meeting the 
criteria for inclusion/exclusion. Patients were randomly divided in groups. All patients of the main 
group (n=30) were prescribed Urolesan oral capsules, manufactured by PJSC “Kyivmedpreparat” 
for 1 capsule 3 times a day, within 1 month starting from basic therapy under a hospital conditions 
and continuing as preventative therapy in outpatient conditions. The control group (n=30) had base-
line therapy (up to 10 days) at the inpatient stage.
The following examination methods were used: collecting anamnesis; objective examina-
tion; general clinical tests of blood and urine; biochemical blood test; bacteriological analysis of 
urine with the definition of sensitivity to antibiotic drugs; sonography; survey and excretory urog-
raphy or multispiral computer tomography.
Basic therapy included non-steroidal anti-inflammatory drugs, antispasmodics and antibiot-
ic therapy. The total observation period for each patient was 6 months.
The treatment efficiency was evaluated for up to 35 days according to the following scheme.
High efficiency
– The period for the concretions fragments coming out was up to 3 days after ESWL session.
– Pain intensity according to the NRS* scale was < 3 points**
– Inflammatory process elimination was up to 10 days
Moderate efficiency
– The period for the concretions fragments coming out was up to 7– 14 days after ESWL session.
– Pain intensity according to the NRS* scale was 4– 7 points**
– Inflammatory process elimination was up to 30 days
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– The period for the concretions fragments coming out was more than 14 days after 
ESWL session.
– Pain intensity according to the NRS* scale was >7 points**
– Inflammatory process elimination was more than 30 days
Note: * – Numerical Rating Scale (NRS) [13]; ** – Up to 5 days after ESWL session
The drug tolerability was evaluated by the symptoms and subjective feelings, according to 
the patient’s words and objective data obtained during the treatment. The dynamics of laboratory 
parameters, as well as the frequency of occurrence and the nature of adverse reactions also was 
considered.
The drug tolerability was evaluated in points by the following scale: 
1 point – well (no adverse reactions);
2 points – satisfactorily (insignificant adverse reactions, but there is no need in the drug 
withdrawal);
3 points – unsatisfactorily (there is an unwanted side effect having a significant negative 
effect on the patient’s condition and requires the drug withdrawal).
The data defined as efficacy and tolerability criteria were evaluated using the proposed 
scale, statistically processed and compared prior, during and after the treatment. On the basis of 
the obtained results, conclusions concerning the efficacy and safety of the drug were made. The 
Student’s criterion (p) was used to estimate the intergroup differences in attributes that have a 
continuous distribution. The critical level of reliability of the zero statistical hypothesis was 0.05 
and was statistically significant in cases of p <0.05; at p> 0.05 the difference was within the limits 
of statistical error.
5. Results of research 
The complete concretion fragmentation to the fragments size less than 3 mm was achieved 
in all involved patients. The patients having more than one ESWL session were excluded from the 
study. The patients’ complaints at admission were: pain syndrome, which was manifested by an 
attack of the renal colic on the part of obstructive stone concrement of the ureter in all 100 % of 
the patients, but pain syndrome severity during the concretion admission after its fragmentation of 
between the groups was different (Table 1).
Table 1
Pain intensity in both groups of the patients according to the Numerical Rating Scale in different periods of 
observation.
Pain intensity estimation by the Numerical  
Rating Scale, (NRS) in the patients of both  
groups at admission and after ESWL session.  
Hospitalization terms
Pain intensity estimation by 10-points scale 

















At admission – – 6 7 9 9 15 14
After ESWL
Day 1 9 8 5 7 11 9 5 6
Day 3 9 11 7 7 4 8 2 4
Day 5 18 15 9 7 2* 5 1* 3
Note: * – < 0,05
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At inclusion, there were no reliably statistically significant differences between the two 
groups. The control of patients after ESWL was carried out according to sonography and 
X-ray/CT scans.
The initial parameters of the patients in both groups are shown in Table 2. 
Table 2
The initial parameters of the both groups of the patients
Markers Main group (n=30) Control group (n=30) Confidence level, р
The patients  
average age, years 37.8±3.9 38.2±5.2 >0.05
Number of women 17 (56.7 %) 16 (53.3 %) >0.05
Concretion size, cm 0.79±0.6 0.78 ± 0.5 >0.05
Leukocyturia,  
number of patients 17 (56.7 %) 19 (63.3 %) >0.05
Bacteriuria,  
number of patients 11 (36.7 %) 12 (40.0 %) >0.05
Creatinine of  
blood serum, μmoles/l 73.7±6.4 64.2±7.3 >0.05
Daily diuresis, ml 1647±210 1732±192 >0.05
Urine рН 6.5±1.2 5.2±1.0 >0.05
Average number of  
impulses per session, number 1623±205 1657±197 >0.05
According to the urine bacteriological study in the main group, bacteriuria was observed 
in 11 (36.7 %) patients, in the control group in 12 (40.0 %) patients. The most commonly isolat-
ed pathogens in the titers >10*4 CFUs were: E. coli in 8 (72.7 %/11) patients of the main group 
and 7 (58.3 %/12) patients of the control group, in 2 (18.2 %/11) of the patients in the main group 
and 3 (10.0 %/12) patients of the control group Pr. Mirabilis was found, and Kl.pneumoniae was 
found in 1 (9.1 %/11) patient of the main group and 2 (16.7 %/12) patients in the control group. On 
the 30th day of the study, the pathogens in urine were not found in patients of the main group, and 
one patient of the control group had Kl. Pneumonia. Antibiotic therapy was carried out empirically 
and according to the antibioticogram results. The data concerning urine bacteriological examina-
tion in various terms is displayed in Fig. 1.
After ESWL session, fragments of concretions in the main group came out up to 3 days in 
6 (20.0 %) patients, in the control group in 3 (10.0 %) patients р <0.05; up to 7 days in the main 
group came out in 15 (50.0 %) patients, in the control group in 12 (40.0 %) patients р <0.05; up to 
14 days in the main group came out in 1 (3.3 %) patient, in the control group in 5 (16.7 %) patients 
р <0.05 (Table 3). 
 group, the fragments came out in 21 patients (70.0 %), while in the control group in 15 pa-
tients (50.0 %) (p1−p2, p <0.05) to the 7th day, and in the main group, the fragments came out in one 
patient more than 14 days, and in the control group – in 5 patients, p <0.05.
The “stone path” in the bottom third of the ureter was in 1 patient (3.3 %/30) of the main 
group and in 3 patients (10.0 %/30) in the control group (p1−p2, p <0.05), the period of the “stone 
path” coming out in the patient of the main group was 2.2 days, and in the patients of the control 
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group 4.1 days from the moment of its formation (p1−p2, p<0.05), that confirms the efficiency of 
the Urolesan remedy in treatment of the patients with urolithiatic disease. 
The data concerning the normalization of urine in the patients of both groups are shown 
in Table 4. 
Table 3
Duration of the concretions fragments coming out after ESWL session in the patients of both groups
Duration of the concretions coming out, days Main group (n−30) Control group (n−30)
<3 days, number of patients 6 (20.0 %)* 3 (10.0 %)
<7 days, number of patients 15 (50.0 %)* 12 (40.0 %)
<14 days, number of patients 8 (26.7 %) 10 (33.3 %)
>14 days, number of patients 1 (3.3 %) * 5 (16.7 %) 












Day 0 Day 10 Day 30
Main group n=11
Control group n = 12
Fig. 1. Urine bacteriological examination markers in patients of both groups
Table 4
Terms of the normalization of general urine analysis markers in the patients depending on the therapy scheme 
Research groups
Normalization of the general urine analysis markers
10th day 30th day
abs.  % abs.  %
Main group (n=30) 19 63.3 28 93.4
Control group (n=30) 18 50.0 22 73.3*
Note: * – р<0.05
The pathological changes elimination in the general urine analysis was registered on the 
10th day in 19 patients (63.3 %) in the main group and in 18 patients (50.0 %) in the control group, 
and leukocyturia statistically significant normalization on the 30th day observed in 93.4 % of the 
patients in the main group in relation to 73.3 % of patients in the control group (p1−p2, p<0.05), 
which proves the expediency of phytotherapy.
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5. Discussion of results of the study
The intensity of the pain syndrome in patients of both groups did not differ at admission, 
but the best results were observed in the patients of the main group on the 3rd day, and statistically 
significantly better markers were determined on day 5 (p<0.05).
Gaponenko A. D. and coauthors proved in their study that Urolesan reduce spasms and pain 
in the urinary tract. Besides, it reduces renal tissue swelling, increases diuresis, therefore, concre-
ments or their fragments come out faster. Urolesan contains components that increase renal blood 
flow and stimulate the removal of urea and chlorides from the blood and lead to normal urine pH, 
has anti-inflammatory and antimicrobial activity [15].
In our study, the statistical significance of changes in the following criteria between pa-
tients in the two groups is observed, namely: before the 7th day, in the main group, the fragments 
came out in 21 (70.0 %/30) patients, and in the control group in 15 (50.0 %) patients (p1–p2, 
p<0.05), the fragments came out in one patient of the main group more than 14 days, and in 5 pa-
tients (p <0.05) of the control group indicating the high efficiency of phytotherapy in patients of 
the main group.
According to OF. Miller data, concretions up to 4 mm come out independently in 95 % of 
cases, without any complications. Concretions sized >6 mm, as a rule, are treated by active meth-
ods, but in some cases they can come out independently [16]. According to the recommendations of 
the European Association of Urology, patients with concretions sized up to 5 mm without any rea-
sons for their active removal, are recommended to have conservative treatment (evidence level 1a) 
[17]. In such cases, MET (medically expulsive therapy) is used, which promotes the spontaneous 
coming out of concretions, but it should be stopped in case of complications (intolerable pain, 
infection, dysfunction of the kidneys) (evidence level 1a) [18]. Using meta analysis, it was proved 
that concretions came out quickly in patients who took alpha-adrenoblockers and calcium channel 
blockers [18].
However, the data from several recent well-planned randomized clinical trials did not shown 
the MET benefits in patients with ureteric stones [19, 20].
The effectiveness of the ESWL use in patients with ureteric stones, according to various 
authors, varies from 60 % to 85 % and depends on the localization, size, chemical composition, 
duration of the stone in the ureter and complications [21]. Although ESWL is the least invasive 
procedure with the lowest level of complications, ureterroroscopy is a minimally invasive method 
that achieves stone-free in the greatest number of cases (level of evidence 1a) [22].
One of the ureteric concretions ESWL complications is the “stone path” in the bottom third 
of the ureter, which was found in one patient in the main group and 3 patients in the control group, 
and the healing period of the “stone path” in the patient of the main group was 2.2 days, and in 
patients of the control group was 4.1 days from the moment of its formation, which confirms the 
efficiency of Urolesan in the treatment of patients with urolithiatic disease.
Coptcoat and coauthors indicate 3 types of the “stone path”: the 1st type is accumulation of 
sand and small (up to 2 mm) fragments – is the most common type; the 2nd type is intruded “leading 
fragment”, and above it there is a cluster of sand and small (up to 2 mm) fragments; the 3rd type is 
accumulation of large fragments. It is evident that the emergence of Type 2 and Type 3 is due to the 
lack of concrete fragmentation [23].
Amino acids of medicinal herbs (which involved in biosynthesis, transport and increase 
the bioavailability of other groups of biologically active substances), including Methionine and 
Glutamic acid play a significant role in treatment of urolithiatic disease and inflammatory diseases 
of kidneys and bladder; they are included the finished drugs (of synthetic origin), even in standard 
therapy with phosphate type of stone formation [24]. Due to the presence of terpenoids and poly-
phenols of flavonoid nature, phytotherapeutic remedies have a mild sedative and antispasmodic 
effect, which is very important in concrements coming out.
The essential oils terpene components of various structures, as a part of Urolesan compo-
sition, reduce the severity of inflammatory processes, increase the kidneys and liver blood supply, 
show diuretic, choleretic, and bactericidal effect, as well as normalize the tone (reduce spasm) of 
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smooth muscles of the upper urinary tract and gall bladder. By stimulating kidney and liver blood 
circulation, terpenoids cause an increase in urination and biliary excretion [25].
According to A. G Chuchalin and coauthors data (2011), herbal remedies, as well as syn-
thetic retinol and alpha tocopherol are used to preserve the crystalloid stability of urine in standard 
therapy [26], which are included in the composition of Urolesan in their natural form (carotenoids, 
and fatty acid fraction tocopherols), which significantly increase their bioavailability and efficiency 
compared to synthetic analogues.
Normalization of the general analysis of urine parameters up to the 30th day is better by 
20 % in patients of the main group than in patients of the control group. On the 10th day, bacteriuria 
in the main group at 6.6 % less than in the control group was observed.
For polyphenols, and in particular flavonoids (including anthocyanins, catechins), anti-in-
flammatory, capillary stabilizing, anti-oxidant types of action are proven. Vitamins, in particular, 
tocopherols [26], which enter the body with the fatty acid fraction and Urolesan herbal component, 
are also extremely important in reducing of the crystallization, increase and aggregation of calcium 
oxalate and calcium phosphate in urine. Pyridoxine promotes reduction in the oxalic acid synthesis 
and stimulates processes of its neutralization in liver [27].
A comparative analysis of the clinical and laboratory efficacy of the treatment of patients 
using ESWL for concretions in one third of the ureter showed that the normalization of the general 
analysis of urine parameters in the patients of the main group was faster than in patients in the 
control group.
Therefore, at comparing the results of both groups, it was noted that high efficacy of treat-
ment was registered in 6 (20 %) patients of the main group and in 3 (10 %) patients of the control 
group (p<0.05), the moderate efficiency of the treatment was registered in 23 (76.7 %) patients of 
the main group and 22 (73.3 %) patients of the control group respectively, low efficiency was regis-
tered in 1 (3.33 %) patient of the main group and 5 (16.7 %) patients of the control group (p<0.05). 
However, for more accurate data and clarification of the indications and contraindications, the 
further studies of Urolesan, which demonstrated high efficacy and the absence of adverse effects, 
should be carried out.
No patient of the main group had side effects, so all patients of the main group had 1 point 
of Urolesan capsules tolerability.
6. Conclusion
1. In patients of the main group, the concretions fragments came out faster relative to the 
control group, namely before the 7th day, in the main group, the concretions fragments came out in 
21 (70.0 %/30) patients, and in the control group in 15 (50.0 %) patients (p1−p2, p<0.05), more than 
14 days concretions fragments came out in one patient (3.3 %) in the main group, and in 5 (16.7 %) 
patients in the control group (p<0.05 ). The “stone path” in the bottom third of the ureter was in 1 
(3.3 %/30) patient in the main group and in 3 (10.0 %/30) patients in the control group (p <0.05).
2. The use of herbal medicine helps to reduce pain syndrome. In the patients of the main 
group after the ESWL session of concretions in third part of the ureter: 7−10 points according to 
the Numerical Rating Scale (NRS) on the fifth day was in one patient (3.3 %) in the main group, in 
3 (10.0 %) patients in the control group (p <0.05).
3. Results of the study showed high efficience, safety and tolerability of Urolesan capsules, 
in the treatment of patients with the concretions in third part of the ureter after the ESWL session.
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